Free CE/CME Activities

Browse free continuing education activities across medical specialties

Clinical Crossroads™: The Importance of Considering Lambert-Eaton Myasthenic Syndrome (LEMS) in the Differential DiagnosisFree CE/CME
From Chair to Care Plan—Applying Evidence to Patient-Centered ManagementFree CE/CME

From Chair to Care Plan—Applying Evidence to Patient-Centered Management

Ophthalmology, Optometry

Available through July 1, 2027

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

CMECOPE
Timing Is Everything—Onset, Duration, and Dosing in Real-World CareFree CE/CME

Timing Is Everything—Onset, Duration, and Dosing in Real-World Care

Ophthalmology, Optometry

Available through July 1, 2027

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

CMECOPE
From Dropout to Long-Term Wear—A Case-Based Approach to Personalized Contact Lens CareFree CE/CME

From Dropout to Long-Term Wear—A Case-Based Approach to Personalized Contact Lens Care

Ophthalmology, Optometry

Available through July 1, 2027

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

CME
Expanding the Fit—Mastering Toric and Multifocal Success in Complex PatientsFree CE/CME

Expanding the Fit—Mastering Toric and Multifocal Success in Complex Patients

Ophthalmology, Optometry

Available through July 1, 2027

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

CME
Mechanism Matters—How OTC Therapies Interrupt the Allergic CascadeFree CE/CME

Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade

Ophthalmology, Optometry

Available through July 1, 2027

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

CMECOPE
Modality Matters—Optimizing Contact Lens Selection for Real-World WearFree CE/CME

Modality Matters—Optimizing Contact Lens Selection for Real-World Wear

Ophthalmology, Optometry

Available through July 1, 2027

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

CME
Burst CME™ Part VI: What Does this all Mean for Patients with IgAN?Free CE/CME

Burst CME™ Part VI: What Does this all Mean for Patients with IgAN?

Nephrology

Available through July 1, 2027

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

CME
Burst CME™ Part V: Complement Inhibitors in IgANFree CE/CME

Burst CME™ Part V: Complement Inhibitors in IgAN

Nephrology

Available through July 1, 2027

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

CME
Burst CME™ Part IV: Anti-CD38 Therapies in IgANFree CE/CME

Burst CME™ Part IV: Anti-CD38 Therapies in IgAN

Nephrology

Available through July 1, 2027

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

CME
Burst CME™ Part III: BAFF and APRIL Directed Therapies in IgANFree CE/CME

Burst CME™ Part III: BAFF and APRIL Directed Therapies in IgAN

Nephrology

Available through July 1, 2027

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

CME
Burst CME™ Part II: Endothelin A Receptor Antagonists in IgANFree CE/CME

Burst CME™ Part II: Endothelin A Receptor Antagonists in IgAN

Nephrology

Available through July 1, 2027

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

CME